The emerging role of immune checkpoint inhibitors for the treatment of breast cancer

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Duan Q, Zhang H, Zheng J, et al. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605–618.
   PubMed Web of Science ®Google Scholar
• Repetto L, Giannessi PG, Campora E, et al. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1996;39(2):235–238.
   PubMed Web of Science ®Google Scholar
• Kimmick G, Ratain MJ, Berry D, et al. Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the cancer and leukemia group B (CALGB 9041). Invest New Drugs. 2004;22(1):83–89.
   PubMed Web of Science ®Google Scholar
• Miles DW, Towlson KE, Graham R, et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer. 1996;74(8):1292–1296.
   PubMed Web of Science ®Google Scholar
• Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369–377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu tumors. Cancer Res. 1998;58(21):4902–4908.
   PubMed Web of Science ®Google Scholar
• Miles D, Roché H, Martin M, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16(8):1092–1100.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature. 2012;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 2021;27(1):8–16.
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–867.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–370.
   PubMed Web of Science ®Google Scholar
• Luen S, Virassamy B, Savas P, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241–250.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Delord J-P, Im S-A, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. Clin Cancer Res. 2018;24(12):2804–2811.
   PubMed Web of Science ®Google Scholar
• Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol. 2019;20(3):371–382.
   PubMed Web of Science ®Google Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(1):74–82.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–2467.
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405–411.
   PubMed Web of Science ®Google Scholar
• Winer EP, Lipatov O, and Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. Published online 2021 Mar 4. DOI:https://doi.org/10.1016/S1470-2045(20)30754-3.
   Google Scholar
• Winer EP, Lipatov O, Im S-A, et al. Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. JCO. 2020;38(15_suppl): 1013-1013.
   Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. JCO. 2019;38(1):1–10.
   PubMed Web of Science ®Google Scholar
• Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. JAMA Oncol. 2019;5(3):334–342.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, and Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Emens LA, Adams S, Barrios CH, et al. LBA16 IMpassion130: final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2020;31:S1148.
   PubMed Web of Science ®Google Scholar
• Miles DW, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020;31(suppl_4):S1142–S1215.
   Google Scholar
• Cortes J, Cescon DW, and Rugo HS, et al. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. JCO. 2020;38(15_suppl): 1000-1000. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.1000.
   Google Scholar
• Rugo HS, Schmid P, Cescon DW, et al. Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. SABCS. 2020;GS3–01.
   Google Scholar
• Li B, Dillon LM, Jones J, et al. A comparative study of PD-L1 IHC assays using immune cell scoring and CPS in breast cancer. JCO. 2020;38(15_suppl):e15262–e15262.
   Web of Science ®Google Scholar
• Rugo HS, Loi S, Adams S, et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130. Ann Oncol. 2019;30:v858–v859.
   PubMed Web of Science ®Google Scholar
• Schats KA, Van Vré EA, Boeckx C, et al. Optimal evaluation of programmed death ligand-1 on tumor cells versus immune cells requires different detection methods. Arch Pathol Lab Med. 2018;142(8):982–991.
   PubMed Web of Science ®Google Scholar
• Ge Y, Domschke C, Stoiber N, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother. 2012;61(3):353–362.
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301–1309.
   PubMed Web of Science ®Google Scholar
• Millrud CR, Mehmeti M, Leandersson K. Docetaxel promotes the generation of anti-tumorigenic human macrophages. Exp Cell Res. 2018;362(2):525–531.
   PubMed Web of Science ®Google Scholar
• Grimaldi A, Cammarata I, Martire C, et al. Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. Commun Biol. 2020;3(1):1–13.
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–928.
   PubMed Web of Science ®Google Scholar
• Bachelot T, Filleron T, Bieche I, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat Med. 2021;27(2):250–255.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Garufi G, Palazzo A, Paris I, et al. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert Opin Pharmacother. 2020;21(6):687–699.
   PubMed Web of Science ®Google Scholar
• Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med. 2016;375(1):23–34.
   PubMed Web of Science ®Google Scholar
• Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–684.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39(7):989–998.e5.
   PubMed Web of Science ®Google Scholar
• Liu MC, Robinson PA, Yau C, et al. Abstract P3-09-02: evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: results from the I-SPY 2 TRIAL. Cancer Res. 2020;80(4 Supplement):3-3-09-02.
   Web of Science ®Google Scholar
• Pusztai L, Han HS, Yau C, et al. Abstract CT011: evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: results from the I-SPY 2 TRIAL. Cancer Res. 2020;80(16Supplement):CT011–CT011.
   Google Scholar
• Gianni L, Huang C-S, Egle D, et al. Abstract GS3-04: pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 michelangelo randomized study. Cancer Res. 2020;80(4Supplement):GS3-GS3-04.
   Google Scholar
• Bianchini G, Huang C-S, Egle D, et al. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol. 2020;31:S1145–S1146.
   Web of Science ®Google Scholar
• Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30(8):1279–1288.
   PubMed Web of Science ®Google Scholar
• Loibl S, Schneeweiss A, Huober JB, et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). JCO. 2021;39(15_suppl): 506-506.
   Google Scholar
• Karn T, Denkert C, Weber KE, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;31(9):1216–1222.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, and Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–821.
   PubMed Web of Science ®Google Scholar
• Oncologic Drugs Advisory Committee. Combined FDA and applicant ODAC briefing document. Published 2021 Feb 9. [cited 2021 Feb 11]. Available from: https://www.fda.gov/media/145654/download
   Google Scholar
• Schmid P. KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. ESMO Virtual Plenary. Published online 2021 July 15.
   Google Scholar
• Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020;31(5):569–581.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, and Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–1100.
   PubMed Web of Science ®Google Scholar
• Miglietta L, Repetto L, Gardin G, et al. Tamoxifen and alpha interferon in advanced breast cancer. J Chemother. 1991;3(6):383–386.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167(3):671–686.
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Kalinsky K, Kaklamani VG, et al. A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1). JCO. 2020;38(15_suppl): 1015-1015.
   Google Scholar
• Pérez-García JM, Llombart-Cussac A, Holgado E, et al. Abstract P3-09-03: a phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study). Cancer Res. 2020;80(4Supplement):3-3-09-03.
   Google Scholar
• Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2978–2994.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Kabos P, Beck JT, et al. A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): interim results. JCO. 2020;38(15_suppl): 1051-1051.
   Google Scholar
• Rugo HS, Beck JT, Jerusalem G, et al. Abstract CT108: a phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): preliminary results. Cancer Res. 2020;80(16Supplement):CT108–CT108.
   Google Scholar
• Masuda J, Tsurutani J, Masuda N, et al. Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer: WJOG11418B NEWFLAME trial. SABCS. 2020;12–10.
   Google Scholar
• Abstract OT2-04-02: checkMate 7A8: a phase 2 trial of nivolumab + abemaciclib or palbociclib + anastrozole in postmenopausal women with ER+, HER2−primary breast cancer | cancer research. [cited 2020 Dec 12]. Available from: https://cancerres.aacrjournals.org/content/80/4_Supplement/OT2-04-02
   Google Scholar
• Dieci MV, Guarneri V, Bisagni G, et al. 162MO neoadjuvant chemotherapy and immunotherapy in luminal B BC: results of the phase II GIADA trial. Ann Oncol. 2020;31:S304–S305.
   Web of Science ®Google Scholar
• Cardoso F, Bardia A, Andre F, et al. KEYNOTE-756: randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer. JCO. 2019;37(15_suppl):601–601.
   Google Scholar
• Loi S, McArthur HL, Harbeck N, et al. A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: checkMate 7FL. JCO. 2020;38(15_suppl):604–604.
   Google Scholar
• Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283–1295.
   PubMed Web of Science ®Google Scholar
• Waks AG, Keenan T, Li T, et al. A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC). JCO. 2020;38(15_suppl): 1046-1046.
   Google Scholar
• Huober J, Barrios CH, Niikura N, et al. VP6-2021: iMpassion050: a phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC). Ann Oncol. 2021;32(8):1061–1062.
   Web of Science ®Google Scholar
• Santa-Maria CA, Kato T, Park J-H, et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget. 2018;9(27):18985–18996.
   PubMedGoogle Scholar
• Adams S, Othus M, Patel SP, et al. Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: dart (SWOG S1609, Cohort 36). JCO. 2020;38(15_suppl): 1073-1073.
   Google Scholar
• Brignone C, Gutierrez M, Mefti F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med. 2010;8(1):71.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Armstrong A, Cuypere E, et al. Abstract PD14-08: primary efficacy results from AIPAC: a double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients. Cancer Res. 2021;81(4Supplement):14-14-08.
   Google Scholar
• Amy Jo Chien HHS, University of California SF, H. Lee Moffitt Cancer Center and Research Institute T, et al. Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: results from the I-SPY 2 trial. [cited 2021 May 26]. Available from: https://meetinglibrary.asco.org/record/197500/abstract
   Google Scholar
• Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9(1):1853.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–3720.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5(8):1132–1140.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Postel-Vinay S, Im S-A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–1164.
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533.
   PubMed Web of Science ®Google Scholar
• LoRusso P, Pilat MJP, Santa-Maria CA, et al. Trial in progress: a phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer. JCO. 2020;38(15_suppl):1102–1102.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Llombart-Cussac A, Andre F, et al. KEYLYNK-009: a phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). JCO. 2020;38(15_suppl):596–596.
   Google Scholar
• Schmid P, Loirat D, Savas P, et al. Abstract CT049: phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Res. 2019;79(13Supplement):CT049–CT049.
   Google Scholar
• Schmid P, Savas P, Espinosa E, et al. Phase 1b study evaluating a triplet combination of ipatasertib, atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer. SABCS. 2020;12–28.
   Google Scholar
• MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000;275(50):38953–38956.
   PubMed Web of Science ®Google Scholar
• Dushyanthen S, Teo ZL, Caramia F, et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nat Commun. 2017;8(1):606.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Kim SB, Ž Z, et al. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Ann Oncol. Published online 2021 February 1;32(5):652–660.
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLOS ONE. 2019;14(2):e0212513.
   PubMed Web of Science ®Google Scholar
• Chung H, Saada-Bouzid E, Munoz F, et al. Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: early results from the multicohort phase 2 LEAP-005 study. SABCS. 2020;12–07.
   Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931.
   PubMed Web of Science ®Google Scholar
• Ho AY, Barker CA, Arnold BB, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer. 2020;126(4):850–860.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Krop IE, Trippa L, et al. A phase ii study of pembrolizumab in combination with palliative radiotherapy for hormone receptor-positive metastatic breast cancer. Clin Breast Cancer. 2020;20(3):238–245.
   PubMed Web of Science ®Google Scholar
• McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early- stage breast cancer with comprehensive immune profiling. Clin Cancer Res. 2016;22(23):5729–5737.
   PubMed Web of Science ®Google Scholar
• Comen EA, Bryce Y, Page DB, et al. Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC). JCO. 2019;37(15_suppl): 592-592.
   Google Scholar
• McArthur HL, Comen EA, Bryce Y, et al. 288TiP - A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy. Ann Oncol. 2019;30:v97.
   Google Scholar
• Taylor K, Loo Yau H, Chakravarthy A, et al. An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. J Immunother Cancer. 2020;8(2):e000883.
   PubMed Web of Science ®Google Scholar
• Abstract PD1-03: a multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial | cancer research. [cited 2020 Dec 16]. Available from: https://cancerres.aacrjournals.org/content/80/4_Supplement/PD1-03
   Google Scholar
• Hecht JR, Chan A, Baurain J-F, et al. Abstract P3-09-19: preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer. Cancer Res. 2020;80(4Supplement):3-3-09-19.
   Google Scholar
• Manso L, Villagrasa P, and Chic N, et al. A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early Breast Cancer (REO-027, AWARE-1). SABCS 2020 . 12–08.
   Google Scholar
• Telli ML, Wapnir I, Devitt B, et al. Abstract P3-09-04: phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE- 890/OMS-I141). Cancer Res. 2020;80(4Supplement):3-3-09-04.
   Google Scholar
• Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). JCO. 2020;38(15_suppl): 9503-9503.
   Google Scholar
• Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195.
   PubMed Web of Science ®Google Scholar
• Johannet P, Coudray N, Donnelly DM, et al. Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma. Clin Cancer Res. 2021;27(1):131–140.
   PubMedGoogle Scholar
• Kather JN, Heij LR, Grabsch HI, et al. Pan-cancer image-based detection of clinically actionable genetic alterations. Nat Cancer. Published online 2020 July 27;1–11. DOI:https://doi.org/10.1038/s43018-020-0087-6
   Google Scholar
• Fu Y, Jung AW, Torne RV, et al. Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. Nat Cancer. 2020;1(8):800–810.
   PubMedGoogle Scholar
• Couture HD, Williams LA, Geradts J, et al. Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. Npj Breast Cancer. 2018;4(1):1–8.
   PubMed Web of Science ®Google Scholar
• Howard FM, Dolezal J, Kochanny S, et al. The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021;12(1):1–13.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li Z, Qu J, et al. Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res. 2019;25(12):3538–3547.
   PubMed Web of Science ®Google Scholar
• He G, Howard F, Pandey T, et al. Independent validation of simbiosys tumorscope to predict response to neoadjuvant chemotherapy (NACT) in early breast cancer (EBC). JCO. 2021;39(15_suppl): 582-582.
   Google Scholar
• Magbanua MJM, Swigart LB, Wu H-T, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229–239.
   PubMed Web of Science ®Google Scholar